Loading...
01/11 03:47
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals strong financial performance, with record cash flow and debt reduction. Despite some uncertainties, such as the Boeing contract and supply chain challenges, guidance remains optimistic with expected growth in key sectors. The new share repurchase program further boosts shareholder confidence. The company's market cap suggests moderate volatility, aligning with a positive stock price movement prediction of 2% to 8%.
Revenue $1,050,000,000, up from previous year, driven by stronger demand and pull-in of activity across multiple market sectors.
Non GAAP Operating Margin 6.2%, up 40 basis points sequentially, exceeding guidance due to operational efficiency and late quarter demand surge.
Non GAAP EPS $1.85, exceeding guidance, benefiting from revenue upside, robust operating margin performance, reduced interest expense, and favorable tax rate.
Free Cash Flow (Quarterly) $194,000,000, record performance, contributing to total fiscal 2024 free cash flow of $341,000,000, more than double previous record.
Total Debt Reduction (Quarterly) $102,000,000, contributing to total fiscal 2024 debt reduction of $184,000,000.
Cash Position $347,000,000, up $78,000,000 sequentially.
Gross Margin 10.3%, up 50 basis points sequentially, due to fixed cost leverage and efficiency gains.
Selling and Administrative Expense $54,000,000, above guidance due to additional incentive compensation linked to improved performance.
Cash Cycle 64 days, improved by 19 days sequentially, best result in 4 years, driven by lower accounts receivable and inventory days.
Return on Invested Capital 11.8%, 360 basis points above weighted average cost of capital.
New Manufacturing Programs Won: Plexus won 26 manufacturing programs worth $230,000,000 in annual revenue when fully ramped into production, including significant contributions from the Healthcare Life Sciences market sector.
Healthcare Life Sciences Wins: For fiscal 2024, Plexus generated a record $568,000,000 of program wins in the Healthcare Life Sciences market sector.
Market Share Gains: Plexus gained market share throughout fiscal 2024, positioning the company for solid fiscal 2025.
Aerospace and Defense Growth: Plexus anticipates robust revenue growth in the Aerospace and Defense sector, supported by ongoing share gains and new program ramps.
Healthcare Life Sciences Growth: Expectations for moderate growth in Healthcare Life Sciences, aided by new program ramps and share gains.
Industrial Sector Outlook: Moderate growth is expected in the Industrial sector, reflecting robust growth in semi cap exceeding market recovery forecasts.
Free Cash Flow: Plexus generated record free cash flow of $194,000,000 in the quarter, pushing fiscal 2024 free cash flow generation to $341,000,000.
Operating Margin Achievement: Plexus achieved a non GAAP operating margin of 6.2%, exceeding the long-term goal one year earlier than anticipated.
Cash Cycle Improvement: The cash cycle improved to 64 days, 16 days favorable to expectations, marking the best result in the past four years.
Sustainability Initiatives: Plexus reduced waste to landfill by over 10% globally and reduced Scope 1 and 2 emissions by over 5% across manufacturing sites.
Expansion in Malaysia: Plexus is investing in footprint expansion in Penang, Malaysia, targeting growth in semi cap and healthcare life sciences.
Competitive Pressures: The ongoing uncertainty surrounding Boeing's contract renewal poses a risk to the aerospace and defense sector, which could impact revenue growth.
Regulatory Issues: Plexus has achieved compliance with ASME's nuclear quality assurance standard, which may enhance their competitive position but also requires ongoing adherence to rigorous standards.
Supply Chain Challenges: The company anticipates continued inventory corrections in the Healthcare Life Sciences sector, which may affect revenue growth in the short term.
Economic Factors: Mixed trends within market sectors, particularly in EMEA and industrial markets, indicate potential challenges in maintaining growth momentum.
Demand Volatility: There are concerns regarding program volatility with two customers, which could impact revenue predictability.
Market Uncertainty: The company is cautious about the commercial aerospace subsector, which may affect overall growth projections for aerospace and defense.
Operational Efficiency: While Plexus has achieved strong operational efficiency, any future disruptions in manufacturing processes could impact margins.
Free Cash Flow: Plexus generated record free cash flow of $341,000,000 for fiscal 2024, more than double the previous record.
Operating Margin: Achieved a non-GAAP operating margin of 6.2%, exceeding the long-term goal one year earlier than anticipated.
Market Share Gains: Plexus gained market share throughout fiscal 2024, positioning for solid fiscal 2025.
Sustainability Initiatives: Reduced waste to landfill by over 10% globally and reduced Scope 1 and 2 emissions by over 5%.
New Program Wins: Won 26 manufacturing programs worth $230,000,000 in annual revenue in fiscal Q4.
Fiscal Q1 Revenue Guidance: Guiding revenue in the range of $960,000,000 to $1,000,000,000.
Fiscal Q1 Operating Margin Guidance: Expecting non-GAAP operating margin of 5.7% to 6.1%.
Fiscal Q1 EPS Guidance: Guiding non-GAAP EPS of $1.52 to $1.67.
Fiscal 2025 Revenue Growth: Expect robust revenue growth in Aerospace and Defense, moderate growth in Healthcare Life Sciences and Industrial sectors.
Capital Expenditures: Anticipating capital spending in the range of $120,000,000 to $150,000,000 for fiscal 2025.
Share Repurchase Program: During the quarter, Plexus purchased approximately 166,000 shares of its stock for $19,500,000, completing the previously authorized $50,000,000 share repurchase program. For fiscal 2024, the total spent on share repurchases was $55,700,000 at an average price of $104 per share. A new $50,000,000 share repurchase program was authorized during fiscal Q4.
The earnings call shows a mixed picture. While there is confidence in growth, particularly in the Healthcare and Defense sectors, there are concerns over flat revenue in key areas like Industrial and Aerospace. The Q&A reveals uncertainty in the aerospace sector and reliance on future program ramps. Despite positive guidance and strategic investments, the flat revenue and minor delays temper expectations, leading to a neutral outlook.
The earnings call reveals strong financial performance, with record cash flow and debt reduction. Despite some uncertainties, such as the Boeing contract and supply chain challenges, guidance remains optimistic with expected growth in key sectors. The new share repurchase program further boosts shareholder confidence. The company's market cap suggests moderate volatility, aligning with a positive stock price movement prediction of 2% to 8%.
The earnings call summary shows strong financial performance with record free cash flow, improved margins, and debt reduction. Despite challenges in certain sectors, the company projects robust growth in aerospace and defense and has authorized a new share repurchase program. The Q&A session confirmed strong growth expectations, particularly in aerospace, and highlighted strategic priorities in capital allocation. While there are risks in industrial and EMEA markets, the overall sentiment remains positive, especially with the new program wins and operational efficiencies. Given the market cap, the stock is likely to see a positive movement of 2% to 8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
